Corporate GovernanceApr 30, 2026, 05:08 PM
TVGN 10-K/A Adds Part III Info; Details Exec Comp, 1:50 Reverse Split
AI Summary
Tevogen Bio Holdings Inc. filed an amendment to its 2025 Annual Report on Form 10-K/A to incorporate Part III information, including details on directors, executive officers, corporate governance, executive compensation, and security ownership. This amendment was necessary as the company does not expect to file a definitive proxy statement within the required 120 days. The filing also noted a 1-for-50 reverse stock split effected on March 6, 2026, and provided updated compensation figures for its named executive officers and beneficial ownership data.
Key Highlights
- Tevogen Bio Holdings Inc. filed a 10-K/A to include Part III information (Items 10-14) and update Item 15.
- A 1-for-50 reverse stock split was effected on March 6, 2026, with all share data reflecting this change.
- CEO Dr. Ryan Saadi's total compensation for 2025 was $10,421,000, including $9,920,000 in stock awards.
- CFO Kirti Desai's total compensation for 2025 was $1,230,000, including $930,000 in stock awards.
- Dr. Ryan Saadi beneficially owned 2,489,567 shares (59.45%) as of April 28, 2026.
- Total shares outstanding were 4,187,505 as of April 28, 2026.
- The Audit Committee consists of Victor Sordillo (Chair), Jeffrey Feike (financial expert), and Susan Podlogar.
- 189,356 shares remain available for future issuance under the 2024 Equity Compensation Plan.